{'fraction_non_alphanumeric': 0.03655352480417755, 'fraction_numerical': 0.02610966057441253, 'mean_word_length': 4.9921875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Chloroquine resistant Plasmodium vivax malaria in India

In India, 1·2‐1·5 million new cases of Plasmodium vivax occur each year. These cases are successfully treated with 600 mg chloroquine (adult dose). We report the results of malaria treatment of a 13‐year‐old girl from the Indian Oil Corporation (IOC), Mathura, India who contracted P. vivax infection. The infection failed to respond to 2 cycles of standard chloroquine therapy. The concentrations of chloroquine were monitored with high performance liquid chromatography (HPLC). The plasma and whole blood chloroquine concentrations were 260 and 106 ug/1 respectively, while a 15 µg/1 plasma concentration is considered lethal to P. vivax. Resistance in P. vivax to chloroquine was found at the IOC, Mathura.